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A decreased nitric oxide (NO) bioavailability and an increased oxidative stress play a pivotal role in different cardiovascular
pathologies. As red blood cells (RBCs) participate in NO formation in the bloodstream, the aim of this study was to outline
the metabolic profile of L-arginine (Arg)/NO pathway and of oxidative stress status in RBCs and in plasma of patients with
microvascular angina (MVA), investigating similarities and differences with respect to coronary artery disease (CAD) patients
or healthy controls (Ctrl). Analytes involved in Arg/NO pathway and the ratio of oxidized and reduced forms of glutathione were
measured by LC-MS/MS. The arginase and the NO synthase (NOS) expression were evaluated by immunofluorescence staining.
RBCs fromMVA patients show increased levels of NO synthesis inhibitors, parallel to that found in plasma, and a reduction of NO
synthase expression. When summary scores were computed, both patient groups were associated with a positive oxidative score
and a negative NO score, with the CAD group located in a more extreme position with respect to Ctrl. This finding points out
to an impairment of the capacity of RBCs to produce NO in a pathological condition characterized mostly by alterations at the
microvascular bed with no significant coronary stenosis.
1. Introduction
NO is an important signaling molecule involved in the main-
tenance of vascular function. It promotes several beneficial
effects in the vasculature by inducing vasorelaxation, inhibi-
tion of leukocyte-endothelium adhesion, smoothmuscle cells
migration and proliferation, and platelet aggregation [1, 2]. A
decreased NO bioavailability is well documented in several
cardiovascular diseases, including hypertension, atheroscle-
rosis, and ischemia-reperfusion injury. A reduction of cir-
culating NO species (nitrite and nitrosylated compounds),
which contribute to the total NO availability, is described
in individuals with endothelial dysfunction. The decrease is
correlated with increasing numbers of cardiovascular risk
factors [3–5].
NO is synthesized by the enzymatic action of NO syn-
thases (NOSs), catalyzing the oxidation of the amino acid
L-arginine (Arg) to equimolar amounts of NO and L-
citrulline (Cit), in the presence of oxygen and cofactors.
Although synthesis and release of NO are related to the sub-
strate bioavailability [6], other potential causes of NO defi-
ciency in disease settings have been proposed. Among these,
the high circulating levels of endogenous methylarginines,
that is, symmetric, asymmetric dimethylarginine (SDMA,
ADMA) and monomethylarginine (MMA), act as NO-
synthesis inhibitors [7, 8]. In addition, oxidative stress plays
a pivotal role in determining NO bioavailability by the oxida-
tion of the cofactors/the enzymes involved inNOmetabolism
or by the direct inactivation of NO.
Endothelial cells are considered the major source of NO
in the vasculature; however, it has been shown that also cir-
culating cells may contribute to NO synthesis, that is, plate-
lets, monocytes, and red blood cells (RBCs). RBCs express
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functional NOS [9, 10], similar to the enzyme of endothelial
cells [11], which serves as an intraluminal NO source and
contributes to the regulation of systemic blood pressure [12].
In addition, the transporter for cationic amino acids [13] and
all the enzymes involved in dimethylarginine metabolism
(synthesis and catabolism) [14] have been identified in RBCs.
HumanRBCs also express the enzyme arginase that competes
with NOS for their common substrate Arg to form L-
ornithine (Orn) [15]. Two different isoforms of arginase are
expressed in human [16] and, recently, it has been shown
that arginase I plays an essential role in the control of RBC-
NOS function and in the release of bioactive NO [17]. Indeed,
in experimental models of atherosclerosis [18], myocardial
ischemia [19], hypertension [20], and ageing [21], arginase
activity has been reported to be upregulated at vascular level.
Microvascular angina (MVA) is a pathological condition
characterized by the typical anginal pain, electrocardio-
graphic (ECG) abnormalities at rest (ST-segment depression
or T-wave inversion), all features that increase during exer-
cise, in the presence of nonobstructed epicardial coronary
arteries [22–24]. Even if the pathophysiology of MVA has
not been disentangled yet, insulin resistance, abnormal auto-
nomic control, enhanced sodiumhydrogen exchange activity,
abnormal cardiac sensitivity, and microvascular spasm have
been proposed as potential causes [25]. In addition, increased
concentrations of circulating C-reactive protein have been
shown to correlate with vascular abnormalities in patients
with MVA, suggesting a role of inflammation in this patho-
logical condition [26].
Oxidative stress per se, either directly or through the
reduction of NO bioavailability leading to an impairment
of endothelium dependent vasodilation, has been involved
in the pathophysiology of MVA [27, 28]. In particular,
impaired endothelium-dependent vasodilatation of the coro-
nary microvasculature [27] and its related impaired function,
which limits coronary flow reserve [28–30], have been pro-
posed to induce MVA syndrome.
Alterations in flow-mediated coronary dilation are a fre-
quent finding in patients with MVA. In the microcirculation,
blood flow is largely dependent on hemorheological prop-
erties, particularly RBC deformability, whose importance
increases in capillaries compared with larger vessel [31]. A
decreasedRBCdeformability has been shown in patientswith
CAD and diabetes mellitus [32] and it has been related to a
decreased NO release [33]. In addition, due to the structural
properties and blood flow in the microcirculatory bed, blood
cells are in close contact with endothelium. As it has been
shown that eNOS expression decreases in the microvascula-
ture [34], it could be speculated that within capillaries RBC-
NOS may play a more decisive role [35].
Moreover, it has been recently shown that in patients with
cardiac syndrome X an increase of red cell distribution width
(RDW), a measurement of size variability, and of erythro-
cytes, occurs [36]. Even if it has been reported that reduction
of nitrate and nitrite, coupled to increases in ADMA and
SDMA, occurs in plasma of MVA patients [37, 38], no
information on the levels of the single components of the
NO pathway in RBCs is available yet. Thus, in this study, we
have characterized oxidative stress and the NO biosynthetic
pathway in RBCs of MVA patients in comparison to patients
with coronary artery disease (CAD)or healthy subjects (Ctrl).
2. Methods
2.1. Study Population. Patients with MVA (𝑛 = 25) char-
acterized by stable effort angina or inducible ischaemia and
reduction of the coronary flow reserve, documented by a
positive stress test (at least 2.0mmhorizontal or downsloping
ST-segment depression) or by a positive SPECT, despite the
absence of angiographically documented coronary disease,
were recruited. These patients were compared with angio-
graphically documented CAD patients (𝑛 = 22) and with
subjects deemed as healthy on the bases of the absence of
clinical symptoms, the instrumental and laboratory examina-
tion (Ctrl = 20), and the negative stress test from a previously
described cohort [10]. Exclusion criteria were considered
as follows: a history of congestive heart failure, significant
valvular diseases, hypertrophic cardiomyopathy, vasospastic
angina, recent (<6 months) acute coronary syndrome, sur-
gical or percutaneous revascularization, pacemaker depen-
dency, and atrial fibrillation. Patients with renal insuffi-
ciency (serum creatinine concentration >1.4mg/dL), hepatic
disease, recent infection, recent major surgical interven-
tions, immunological disorders, and chronic inflammatory
or neoplastic diseases were also excluded. This observational
study was carried out in accordance with the Declaration of
Helsinki and approved by the local ethics research committee
of Centro Cardiologico Monzino (number S1687/610). Writ-
ten informed consent to participate was obtained from all
subjects.
2.2. Blood Collection. EDTA-anticoagulated blood was
drawn from the antecubital vein of subjects while fasting
to obtain whole blood, plasma, and erythrocyte samples.
After centrifugation (1,200 g for 10min at 4∘C), plasma was
separated and aliquots were stored at −80∘C until analyses.
Aliquots of packed red cells were lysed by cold deionized
water to obtain lysed RBCs and stored at −80∘C until
analyses.
2.3. Arg/NO Metabolic Pathway. We simultaneously mea-
sured Arg, ADMA, SDMA, MMA, Cit, and Orn by liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
[39]. The ratio Arg/(Orn +Cit), as index of global Arg
availability [40, 41], and the ratio Orn/Cit, as indicator of the
relative activity of arginase and NOS [19], were computed.
All the determinations were performed both in plasma and
in lysed RBCs.
2.4. Oxidative Stress. It was evaluated by the ratio between
disulphide and reduced forms of glutathione (GSSG/GSH).
GSH and GSSG were measured by LC-MS/MS method on
whole blood, after proteins precipitation with trichloroacetic
acid [42]. Levels of GSH and GSSG were expressed as 𝜇mol/g
Hb.
2.5. RBC-NOS and Arginase Expression. The RBC-NOS
expression was performed by immunofluorescence analysis
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in a subgroup of subjects (𝑛 = 10 per group matched for age
and sex). RBCs slides were prepared as previously described
[10]. Briefly, after blocking of nonspecific reactive sites,
RBCs were incubated overnight at 4∘C with a monoclonal
anti-eNOS (2.5 𝜇g/mL) (BD Biosciences, Milano, Italy) or
polyclonal anti-arginase I or monoclonal anti-arginase II
(4 𝜇g/mL, for both) (Santa Cruz Biotechnology, DBA Italia
s.r.l., Milano, Italy) antibodies. After three washings, an anti-
mouse or anti-rabbit AlexaFluor488 conjugated secondary
antibody (Invitrogen, Life Technologies Italia, Monza, Italy)
was added and the immune complexes were visualized by
laser scanning confocal microscope (LSM710, Carl Zeiss,
Milano, Italy) using a 63x/1.3 oil immersion objective lens.
Imageswere captured and the fluorescence intensity (densito-
metric sum of grey) was quantified. Data are expressed as the
mean level of fluorescence intensity, subtracted of negative
control value obtained on the same slide in the absence
of primary antibody. Multiple fields of view (at least three
randomly selected areas) were captured for each slide.
2.6. Statistics and Scores Development. Numerical variables
were summarized as mean and standard deviation (SD),
unless otherwise stated, and categorical variables were sum-
marized as frequencies and percentages. A sample size of
20 subjects per group allowed a statistical power of 90% to
deem as significant a between-group difference in any analyte
approximately equal to one standard deviation, with an alpha
error of 0.05. Variables were compared between MVA and
CAD or Ctrl by 𝑡-test or by covariance analysis, adjusting
for age and sex. Variables with skewed distribution were log-
transformed before analysis. Immunofluorescence intensity
was compared between groups by repeated measures covari-
ance analysis, taking into account replicate measures for each
subject. All analyses were performed by SAS v. 9.2 (SAS
Institute Inc., Cary, NC, USA).
In order to provide a global indicator of all the variables
related to NO pathway and to contain inflation of alpha
error due to multiple testing, we developed a score similar
to the OXY-SCORE, devised by our group few years ago [43].
First, to account for different measurement ranges and units,
all the variables were standardized; that is, the mean was
subtracted from individual values and the result was divided
by the standard deviation. Second, the standardized values of
the variables generally accepted as positively associated with
endothelial function (Arg and Cit) were added, whereas stan-
dardized values of the variables negatively associated with
endothelial function (ADMA, SDMA, MMA, and Orn) were
subtracted. It is important to note that these associationswere
intended as “a priori” and were not inferred from the present
study. We created a first score using variables measured in
plasma (NO plasma score) and another score using variables
measured in the RBCs (NO RBC score). Similarly, we created
oxidative stress score, a simplified version of theOXY-SCORE
including GSSG (with a plus sign) and GSH (with a minus
sign).
3. Results
3.1. Population. Theprincipal demographic and clinical char-
acteristics of the two patient groups and of healthy subjects
analyzed in this study are depicted in Table 1. No significant
differenceswere found among groups except for age (𝑃 = 0.01
MVA versus CAD) that was considered as a confounder for
group comparisons.
3.2. Biochemical Determinations of Metabolites Involved in
Arg/NO Pathway and Oxidative Stress Status. In order to
evaluate the potential impairment of Arg/NO pathway in
MVA patients, we simultaneously measured the principal
metabolites involved in this pathway, both in plasma and in
the RBC compartment, and we compared them to the levels
measured in CAD and in Ctrl (Table 2). In plasma, MVA
patients showed Arg, Cit, and Orn levels similar to those of
CAD patients and Ctrl. ADMA levels, instead, were higher
in bothMVAandCADpatients compared toCtrl. SDMAand
MMA levels did not differ among the three groups studied.
In accordance to these findings, the Arg bioavailability
(Arg/Orn +Cit ratio) was lower in MVA than in Ctrl and
similar to CAD. In addition, theMVAOrn/Cit ratio, an index
of activities of the Arg metabolic enzymes arginase and NOS,
showed levels intermediate between those of CAD and Ctrl
(Table 2).
In the RBC compartment, the levels of NO inhibitors
ADMA and SDMA in MVA and CAD patients were higher
than in Ctrl (Table 2). Interestingly, MMA levels were the
highest in MVA. Arg bioavailability was similar in the three
groups of subjects, whereas the Orn/Cit ratio was signifi-
cantly lower in MVA than in CAD group but similar to Ctrl
(Table 2).
Patients with MVA had higher levels of oxidative stress
with respect to Ctrl, but lesser than those determined in CAD
patients, as documented by the GSSG/GSH ratio measured
in whole blood (Figure 1(a)). Specifically, both groups of
patients showed lower levels of GSH and higher levels of
GSSG with respect to Ctrl (Figure 1(b)).
Figure 2 shows the distribution of the analytes measured
in plasma or RBCs of MVA and CAD patients expressed as
fold change over Ctrl. In general, the analytes of the NO
pathway behaved similarly in MVA and CAD and they were
moderately elevated with respect to Ctrl, both in plasma and
in RBCs. A special case is represented by MMA in RBCs,
whose levels were higher in MVA with respect to Ctrl and
CAD patients. As expected, the oxidative stress, in particular
the oxidized form of glutathione, was higher in both MVA
and CAD patients with respect to Ctrl.
3.3. Arginine Metabolic Enzymes: RBC-NOS and Arginase.
The expression of RBC-NOS, visualized by immunofluo-
rescence staining, revealed strong quantitative differences
between both patient groups and Ctrl. RBCs of MVA and
CAD patients had significantly lower RBC-NOS fluores-
cence, localized in the membrane and into the cytosol, with
respect to Ctrl (Figure 3(a)).
The expression of both isoforms of arginase was also eval-
uated. RBCs ofMVA patients and of Ctrl expressed lesser lev-
els of arginase I than CAD patients (𝑃 = 0.02) (Figure 3(b)).
In contrast, the expression of arginase II was not detectable in
RBCs of Ctrl and of MVA or CAD patients (data not shown).
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Table 1: Demographic and clinical characteristics of the subjects.
Variable MVA (𝑛 = 25) CAD (𝑛 = 22) Ctrl (𝑛 = 20)
Age (years) 56.5 ± 10.3 66.1 ± 8.6 55.5 ± 10.2
Male gender 14 (56.0) 17 (77.3) 14 (70)
BMI 25.8 ± 3.3 27.3 ± 3.11 24.36 ± 2.35
Total cholesterol (mg/dL) 226.9 ± 59.2 208.3 ± 29.2 208.1 ± 26.8
HDL-cholesterol (mg/dL) 54.9 ± 17.3 46.9 ± 17.2 54.5 ± 17.3
LDL-cholesterol (mg/dL) 150.0 ± 52.4 133.8 ± 36.8 132.3 ± 22.1
Triglycerides (mg/dL) 105.5 ± 66.9 131.5 ± 69.4 95.5 ± 32.5
Systolic blood pressure (mmHg) 130.0 ± 13.2 138.9 ± 18.3 130.0 ± 14.0
Diastolic blood pressure (mmHg) 78.0 ± 8.3 80.0 ± 9.1 78.0 ± 6.0
Creatinine (mg/dL) 0.85 ± 0.22 0.86 ± 0.22 0.81 ± 0.14
Current smoker 3 (12.0) 3 (13.64) 0 (0)
Hypercholesterolemia 14 (56.0) 14 (63.6) 2 (12.5)
Hypertriglyceridemia 1 (4.0) 2 (9.1) 1 (6.25)
Hypertension 11 (44.0) 14 (63.6) 2 (12.5)
Pharmacological treatments
Converting enzyme inhibitors 2 (8.0) 6 (27.3) 0 (0)
Antithrombotics 23 (85.1) 17 (77.3) 0 (0)
Beta-blockers 10 (40.0) 5 (23.8) 1 (5.88)
Calcium channel blockers 1 (4.0) 4 (18.2) 1 (5.88)
Diuretics 2 (8.0) 2 (9.1) 0 (0)
Statins 4 (16.0) 4 (18.2) 2 (11.8)
Hypoglycemics 0 (0) 0 (0) 0 (0)
Angiotensin receptor blockers 4 (16.0) 6 (27.3) 0 (0)
Quantitative variables are expressed as mean ± SD and categorical variables as 𝑛 (%).
Table 2: Biochemical determinations in plasma and RBCs.
Plasma RBC
MVA (𝑛 = 25) CAD (𝑛 = 22) Ctrl (𝑛 = 20) MVA (𝑛 = 25) CAD (𝑛 = 22) Ctrl (𝑛 = 20)
Arg 74.22
[69.15–87.08]
82.88
[64.81–95.74]
84.80
[73.13–98.01]
7.57
[5.00–9.53]
8.64
[5.31–10.48]
6.84
[3.86–7.80]
Cit 27.45
[24.21–31.16]
27.61
[20.41–33.83]
26.55
[24.13–30.68]
11.36
[9.58–12.35]
10.48
[8.36–12.11]
8.37
[7.04–10.78]
Orn 47.66
[41.19–54.11]
51.82
#
[48.72–61.68]
40.84
[34.09–46.08]
39.48
[29.52–49.06]
42.59
[36.74–44.90]
33.93
[23.77–43.07]
ADMA 0.51
#
[0.43–0.60]
0.49
#
[0.45–0.59]
0.41
[0.35–0.47]
0.18
#
[0.14–0.27]
0.20
#
[0.15–0.25]
0.15
[0.12–0.20]
SDMA 0.47
[0.42–0.60]
0.54
[0.45–0.63]
0.42
[0.36–0.48]
0.13
##
[0.09–0.16]
0.13
#
[0.12–0.15]
0.10
[0.06–0.11]
MMA 0.12
[0.09–0.13]
0.11
[0.08–0.13]
0.12
[0.10–0.14]
0.13
∗
[0.07–0.18]
0.05
[0.04–0.09]
0.09
[0.05–0.12]
Arg bioavailability 1.06
#
[0.90–1.26]
1.01
#
[0.87–1.22]
1.25
[1.04–1.41]
0.13
[0.11–0.19]
0.16
[0.12–0.19]
0.14
[0.09–0.20]
Orn/Cit ratio 1.74
[1.42–2.21]
1.97
###
[1.69–2.40]
1.48
[1.36–1.71]
3.88
∗
[3.10–4.41]
3.96
[3.51–5.03]
3.92
[3.20–4.32]
Quantitative variables are expressed as median [interquartile interval]. ∗𝑃 < 0.05 versus CAD; #𝑃 < 0.05, ##𝑃 < 0.01, and ###𝑃 < 0.001 versus Ctrl adjusted
for age and gender after log-transformation of the data.
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Figure 1: GSSG/GSH ratio in whole blood.The results are expressed
as mean ± SE for GSSG/GSH ratio (a) or as median (interquartile
range) (b) in whole blood from patients with microvascular angina
(MVA 𝑛 = 25) or coronary artery disease (CAD 𝑛 = 22) or healthy
subjects (Ctrl 𝑛 = 20). ∗𝑃 < 0.05 versus CAD, #𝑃 < 0.05, ###𝑃 <
0.001 versus Ctrl.
3.4. Summary Scores of NOPathway andOxidative Stress. The
analytes, that is, substrate, inhibitors, and enzymatic products
involved in NO synthesis, were combined into appropriate
scores (see Section 2) in order to summarize the Arg/NO
pathway in the examined clinical settings. In Figure 4, the
Cartesian plane was defined by the NO plasma score (𝑥-axis)
and the NO RBC score (𝑦-axis); the intersection of the axes
identifies the midpoint of the entire sample, and the units are
expressed in terms of standard deviations.TheCtrl groupwas
placed in the first quadrant (positive values for both scores),
whereas the two patient groups were placed in the third
quadrant (negative values for both scores). To be noticed,
the MVA group was located in a more negative position,
along theNORBC score axis, comparedwith the CADgroup;
however, the difference did not reach statistical significance.
Figure 5 shows the Cartesian plane defined by the oxida-
tive stress score (𝑥-axis) and the NO plasma score (𝑦-axis). In
this graph, the control groupwas placed in the quadrant char-
acterized by a negative oxidative score and by a positive NO
score. In contrast, both groups of patients were placed in the
quadrant relative to a positive oxidative score and a negative
NO score, with the CAD group located in a more extreme
position with respect to MVA (although this difference did
not reach statistical significance: 𝑃 = 0.08 for multivariate
ANOVA).
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RBC Orn
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RBC Arg
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Figure 2: Levels of analytes involved in Arg/NO pathway measured
in plasma and in RBCs isolated from patients with microvascular
angina (MVA 𝑛 = 25) or coronary artery disease (CAD 𝑛 = 22)
or healthy subjects (Ctrl 𝑛 = 20). The results are expressed as fold
change over Ctrl.
4. Discussion
The study described above shows for the first time that RBCs
of patients with MVA contain higher levels of inhibitors
of the NO synthesis than Ctrl and that these levels do
not markedly differ from those found in CAD patients. A
similar picture is found in plasma, as previously described
by others [37, 38]. Finally, NOS expression in RBCs was
found markedly reduced in both MVA and CAD patients. In
addition, oxidative stress was found increased in both patient
groups, mostly in CAD.
The pathophysiology of MVA is not completely under-
stood yet, even if the several metabolic, haemodynamic, and
vasospastic alterations have been linked to this syndrome.
Recently, it has been reported that RDW values are signif-
icantly higher in both MVA and CAD patients compared
to healthy subjects [36]. However, as documented by the
absence of modifications in RDW values (data not shown),
in our study, the impairment of NO pathway in RBCs of
MVA patients is not associated with changes in the size
of circulating RBCs. The RBCs of MVA patients, however,
showed higher levels of NO synthesis inhibitors and this
finding parallels the data found in plasma. As a consequence,
in a Cartesian plane, defined by NO scores, the MVA group
was located in a negative position along the NO RBC score
axis with respect to Ctrl, thus suggesting a possible alteration
in NO production, more pronounced inMVAwith respect to
CAD.
The limitation of our study might be the calculation of
the NO scores without measuring NO itself. This highly
reactive molecule and its active metabolites are influenced
by several factors, including dietary nitrate intake and renal
function, particularly in the plasma compartment. Thus, we
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Figure 3: NO synthase and arginase expression in human RBCs. Representative immunofluorescent images (630x magnification) of RBCs
isolated from patients with microvascular angina (MVA) or coronary artery disease (CAD) or healthy subjects (Ctrl), stained for RBC-NOS
(a) or arginase I (b). Data are expressed as the mean of fluorescent intensity ± SD subtracted of the negative control value (at least three fields
were analyzed, 𝑛 = 10 subjects for each group). ∗𝑃 < 0.05 versus CAD; #𝑃 < 0.05, ###𝑃 < 0.001 versus Ctrl.
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Figure 4: Arg/NO pathway score in plasma and in RBCs. The
scores are computed after standardization of the analytes involved
in NO synthesis (Arg, Cit, Orn, ADMA, SDMA, and MMA).
The standardized values of the variables positively associated with
endothelial function are added, whereas the values of variables
negatively associated with endothelial function are subtracted. The
NO score is calculated in plasma and in RBC compartment. NO
RBC score: 𝑃 < 0.05MVA versus Ctrl; NO plasma score: 𝑃 < 0.001
MVA versus Ctrl and CAD versus Ctrl.
−3
−2
−1
0
1
2
3
−2.5 −2 −1.5 −1 −0.5 0 0.5 1 1.5 2
N
o 
pl
as
m
a s
co
re
Oxidative stress score
MVA
CAD
Ctrl
Figure 5: NO plasma and oxidative stress scores. The NO plasma
score is computed after standardization of the analytes involved
in NO synthesis (Arg, Cit, Orn, ADMA, SDMA, and MMA).
The standardized values of the variables positively associated with
endothelial function are added, whereas the values of variables
negatively associated with endothelial function are subtracted. The
oxidative stress score is calculated by the values of GSSG (plus sign)
and GSH (minus sign). NO plasma score: 𝑃 < 0.001 MVA versus
Ctrl and CAD versus Ctrl; oxidative stress score: 𝑃 < 0.001 MVA
versus Ctrl and CAD versus Ctrl.
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cannot exclude that other NOS independent factors may add
additional information for an overall picture of thismetabolic
pathway in MVA.
Of interest is the observation that, similar to what pre-
viously described for CAD patients [10], we found a marked
reduction in NOS expression in RBCs of MVA patients. This
finding is of particular relevance because RBCs have a sys-
temic impact in terms of NO production and may represent
an important compartment, whose alteration participates to
the reduction in the overall NO production.
Arg is the substrate for theNOS enzymes, including RBC-
NOS, and it has been shown that an increase of substrate
availability in the stenotic lesion induced dilation of the coro-
nary artery segment [44]. Arg is also substrate for the arginase
enzyme, whose activity is increased in different pathologi-
cal conditions associated with a reduction of NO [17, 45].
Two different isoforms of arginase are identified in
human and arginase I, which is the only arginase so far
described in RBCs, accounts for about 98% of total blood
arginase activity [46]. In our condition, greater amounts of
arginase I in CAD patients, but not in MVA patients, were
found. Since it has been reported that erythroid progenitor
cells express both arginase I and arginase II [15], wemeasured
also this enzyme in RBCs. According to the literature [17], we
failed to detect measurable amounts of arginase II in Ctrl or
in patients.
Increased erythrocyte arginase activity associated with
lowered NO plasma levels and with impairment in erythro-
cytes has been reported in sickle cell disease patients [40].
Interestingly, the consumption of cocoa flavanols reduced the
erythrocyte arginase activity, suggesting a possible therapeu-
tic intervention by the regulation of Arg andNO bioavailabil-
ity [47].
An important condition able to affect NO bioavailability
is oxidative stress. Of relevance is the observation that the
ratio between oxidized and reduced glutathione was almost
doubled in whole blood of MVA patients, suggesting an
increased oxidative stress in this condition. A role of oxidative
stress in lowering NO bioavailability has been previously
highlighted, but the information in MVA is still scanty [27,
48, 49]. We found a marked increase of GSSG/GSH, based
on the increase of oxidized glutathione, which was evenmore
pronounced in CAD patients and on a decrease of GSH
in MVA patients. This observation is in accordance with
data reported by Dhawan et al. [50], who showed a positive
correlation between GSH levels and coronary flow velocity
reserve, thus predicting impaired microvascular function.
Finally, the concomitant assessment of oxidative stress
and NO pathway in patients indicates that both MVA and
CAD patients are placed in the Cartesian plane quadrant
relative to a positive oxidative score and a negative NO score,
with the CAD group located in a more extreme position with
respect to MVA.
Thus, as previously suggested by Rassaf and collaborators
[51], a multiple-level approach by assessing biochemical,
structural, and functional changes in the vasculature may be
important for an early diagnosis of cardiovascular diseases
and for a better characterization of this multifactorial disease.
5. Conclusion
Our study shows that changes in the Arg/NO metabolic
profile, coupled to increases in oxidative stress, occur in
MVA with a trend toward an impairment similar to that of
CAD patients. In particular we have described for the first
time alterations in the capacity of RBCs to produce NO in a
pathological condition characterized mostly by alterations at
the microvascular bed with no significant coronary stenosis.
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